Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE LIPOSOME versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE LIPOSOME versus XYLOCAINE 5 W GLUCOSE 7 5.
BUPIVACAINE LIPOSOME vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine liposome is a long-acting local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx through voltage-gated sodium channels in neuronal cell membranes. The liposomal formulation provides sustained release of bupivacaine, prolonging analgesic effect.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Local infiltration: up to 266 mg (20 mL of 1.3% or 10 mL of 2.66%) single dose; interscalene brachial plexus block: up to 133 mg (10 mL of 1.3%) single dose; sciatic nerve block in the popliteal fossa: up to 133 mg (10 mL of 1.3%) single dose; adductor canal block: up to 133 mg (10 mL of 1.3%) single dose; max dose 266 mg per procedure.
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 12-24 hours (mean 18 hours) due to prolonged release from liposomal depot; significantly longer than conventional bupivacaine (2-4 hours), reflecting slow absorption rate-limited elimination.
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Primarily hepatic metabolism to 3-hydroxybupivacaine and desbutylbupivacaine; renal excretion of metabolites accounts for ~95% of elimination, with <5% unchanged drug excreted in urine; biliary/fecal excretion minimal (<5%).
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic